Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2024 | Mechanisms of resistance to FLT3 inhibitors in AML and strategies to overcome this

Eunice Wang • 14 Jun 2024
EHA 2024
Acute Myeloid Leukemia Leukemia Azacitidine Gilteritinib Quizartinib Venetoclax

Eunice Wang, MD, Roswell Park Comprehensive Cancer Center, Buffalo, NY, discusses the mechanisms of resistance to FLT3 inhibitors and some combination strategies which may be able to overcome this when treating patients with acute myeloid leukemia (AML). This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Explore the AML Channel banner with headshots of Naval Daver, Eunice Wang, and Thomas Cluzeau

More from Eunice Wang

Managing FLT3-ITD mutant AML in remission
11:47
Managing FLT3-ITD mutant AML in remission
Eunice Wang • 19 Sep 2026
Differentiation syndrome in menin inhibitor-treated patients: recognition, management & next steps
6:18
Differentiation syndrome in menin inhibitor-treated patients: recognition, management & next steps
Eunice Wang et al. • 18 Sep 2026
Targeting FLT3-mutant AML: frontline strategy, MRD-guided transplant, and RAS-targeted approaches
12:28
Targeting FLT3-mutant AML: frontline strategy, MRD-guided transplant, and RAS-targeted approaches
Alexander Perl et al. • 20 Sep 2026
KOMET-007: ziftomenib in combination with venetoclax and azacitidine in R/R AML
1:59
KOMET-007: ziftomenib in combination with venetoclax and azacitidine in R/R AML
Eunice Wang • 5 Dec 2025

Related Videos

Addressing changes to genomic prognostic markers in CLL beyond the chemotherapy era
4:04
Addressing changes to genomic prognostic markers in CLL beyond the chemotherapy era
Anna Schuh • 16 Oct 2026
Understanding the CLL genome: current knowledge and remaining gaps
3:39
Understanding the CLL genome: current knowledge and remaining gaps
Anna Schuh • 16 Oct 2026
How is frontline fixed-duration acalabrutinib plus venetoclax shaping treatment decisions in CLL?
2:00
How is frontline fixed-duration acalabrutinib plus venetoclax shaping treatment decisions in CLL?
Alexey Danilov • 16 Oct 2026
Autoimmune cytopenias in patients with CLL on venetoclax-based therapy: outcomes from an ERIC study
3:39
Autoimmune cytopenias in patients with CLL on venetoclax-based therapy: outcomes from an ERIC study
Marta Coscia • 16 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals